T3 Companies LLC Invests $548,000 in VYNE Therapeutics Inc. $VYNE

T3 Companies LLC bought a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 945,000 shares of the company’s stock, valued at approximately $548,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in VYNE Therapeutics by 64.2% in the fourth quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after purchasing an additional 88,030 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in shares of VYNE Therapeutics in the 2nd quarter valued at about $176,000. Jane Street Group LLC acquired a new position in shares of VYNE Therapeutics in the 2nd quarter valued at about $206,000. Two Sigma Investments LP purchased a new stake in shares of VYNE Therapeutics in the third quarter worth about $74,000. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after buying an additional 300,000 shares during the last quarter. 83.78% of the stock is currently owned by institutional investors and hedge funds.

VYNE Therapeutics Trading Down 1.8%

Shares of VYNE stock opened at $0.66 on Thursday. VYNE Therapeutics Inc. has a 12-month low of $0.28 and a 12-month high of $1.96. The business’s 50 day moving average is $0.65 and its two-hundred day moving average is $0.58. The company has a market capitalization of $21.97 million, a P/E ratio of -1.73 and a beta of 2.00.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.10. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.20 million. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%. On average, research analysts predict that VYNE Therapeutics Inc. will post -1.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of VYNE Therapeutics in a research report on Monday, May 4th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.